Hyperion Therapeutic, Inc.

Hyperion Therapeutics, Inc. (Hyperion) is a privately held specialty biopharmaceutical company engaged in development and commercialization of novel therapeutics to meet the critical unmet needs in the areas of gastroenterology and hepatology. The company is currently focusing on the development of glycerol phenybutyrate (HPN-100), for urea cycle disorders and hepatic encephalopathy. The company obtained the development rights for glyercol phenylbutyrate from Ucyclyd Pharma, Inc. and acquired the worldwide commercialization rights on successful product approval from the US FDA. The company is financed by Bay City Capital, Highland Capital Partners, NEA, Panorama Capital, Sofinnova Ventures, and WRF Capital. The company is headquartered in California, the US.

Street: 
601 Gateway Blvd
City: 
South San Francisco
Postcode: 
94080
Federal State : 
United States
WebSite: 
www.hyperiontx.com
Fax: 
1-650-8717029

Company Index Score

Current Index Score Historical Index Score
  • Hyperion Therapeutic, Inc. currently scores 50 % in the index.
  • Hyperion Therapeutic, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Hyperion Therapeutic, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets